Noopept vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Noopept
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | Noopept | Substance P |
|---|---|---|
| Mechanism | Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |
What They Have in Common
Both Noopept and Substance P are commonly used for: